2021
75 Acute and Chronic Hepatitis
Fawaz R, Jonas M. 75 Acute and Chronic Hepatitis. 2021, 819-837.e6. DOI: 10.1016/b978-0-323-67293-1.00075-x.Peer-Reviewed Original ResearchChronic hepatitisLiver biopsyHepatocellular carcinomaHepatitis B virus infectionAcute hepatitis CChronic hepatitis BB virus infectionPerinatal transmission rateGrade of inflammationAutoimmune hepatitisJaundice 3Transplantation 2Hepatitis CHepatitis BClinical courseHepatitis ANonalcoholic steatohepatitisHistologic featuresPersistent elevationViremia levelsPrimary indicationInfection 5Hepatic damageFamily historyVirus infection
2019
The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus.
Leng W, Wu M, Pan H, Lei X, Chen L, Wu Q, Ouyang X, Liang Z. The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. Annals Of Translational Medicine 2019, 7: 429. PMID: 31700865, PMCID: PMC6803170, DOI: 10.21037/atm.2019.09.03.Peer-Reviewed Original ResearchHFD/streptozotocinHigh-fat dietDiabetes mellitusExperimental steatohepatitisHepatic damageNOD-like receptor family pyrin domainSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsDiabetic liver injuryEfficacy of dapagliflozinROS-NLRP3 inflammasomeSGLT2 inhibitor dapagliflozinHepatic reactive oxygen speciesCotransporter 2 inhibitorsReactive oxygen speciesFamily pyrin domainHepatic lipid accumulationSterile inflammatory responseMajor clinical consequencesDAPA treatmentDM patientsInhibitor dapagliflozinLiver injuryLiver diseaseLiver steatosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply